Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 10/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 10/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966295 | 1.00 | HTT (0.36) | HTTSMN1; SMN2MAPTMCHR1NR2F2 | |
| SCHEMBL961685 | 0.91 | MAPT (0.38) | HTTSMN1; SMN2MAPTNR2F2 | |
| SCHEMBL961684 | 0.91 | MAPT (0.38) | HTTSMN1; SMN2MAPTNR2F2 | |
| SCHEMBL965612 | 0.89 | MAPT (0.36) | HTTSMN1; SMN2MAPTMCHR1NR2F2 | |
| SCHEMBL965616 | 0.89 | MAPT (0.36) | HTTSMN1; SMN2MAPTMCHR1NR2F2 | |
| SCHEMBL965067 | 0.89 | HTT (0.36) | HTTSMN1; SMN2MAPTNR2F2USP2 | |
| SCHEMBL965070 | 0.89 | HTT (0.36) | HTTSMN1; SMN2MAPTNR2F2USP2 | |
| SCHEMBL963652 | 0.88 | FPR2 (0.37) | HTTSMN1; SMN2MAPTMCHR1NR2F2 | |
| SCHEMBL963650 | 0.88 | FPR2 (0.37) | HTTSMN1; SMN2MAPTMCHR1NR2F2 | |
| SCHEMBL28781999 | 0.86 | MCHR1 (0.35) | HTTSMN1; SMN2MAPTMCHR1NR2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | HTT 3376/4885SMN1; SMN2 3745/4885MAPT 4343/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | HTT 3799/4885SMN1; SMN2 4710/4885MAPT 4720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.